INSULET CORP PODD revenue by segment, product and geography
In its fiscal year ending 2025-12-31, INSULET CORP reported revenue across 4 products and services; the largest, Product Omnipod, was $2.67B (+31.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product Omnipod$2.67Bshare n/a+31.5% yoy
- U.S.Omnipod$1.92Bshare n/a+27.2% yoy
- International Omnipod$754Mshare n/a+44.1% yoy
- Drug Delivery$34.1Mshare n/a-12.3% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$1.95B72.1%+26.2% yoy
- Outside the United States$754M27.9%+44.1% yoy
Members sum to the consolidated $2.71B for this period.
- Product Omnipod$758Mshare n/a+36.9% yoy
- U.S.Omnipod$516Mshare n/a+28.4% yoy
- International Omnipod$243Mshare n/a+59.5% yoy
- Drug Delivery$3.3Mshare n/a-77.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.